This ongoing triple-blind, randomized controlled crossover trial investigates the effects of a single ingestion of KE (ketone esters) on signs and symptoms of schizophrenia spectrum disorders (SSDs) and bipolar disorders (BDs).
New Results: First RCT for Schizophrenia & Bipolar Disorder. Learn more.